AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Amyloidosis

Recent research efforts aimed at curing Amyloidosis.

Last updated
Also available in
Français — Amylose

Amyloidosis

Overview

Amyloidosis is a group of disorders in which normally soluble proteins misfold, assemble into tough fibers called amyloid fibrils, and accumulate in organs. The two systemic forms most relevant to current curative research are light-chain (AL) amyloidosis, driven by an abnormal clone of antibody-producing plasma cells, and transthyretin (ATTR) amyloidosis, driven by the liver-produced transthyretin protein—either a hereditary variant or the normal “wild-type” protein that becomes unstable with age. Deposits commonly damage the heart, kidneys, nerves, digestive system, and liver; the prognosis depends greatly on amyloid type, organs involved, and how early treatment begins. In AL amyloidosis, cardiac biomarkers and free-light-chain levels define risk groups with markedly different five-year survival. Current approaches to diagnosis and management AL amyloidosis: 2024 update

Standard care is type-specific and is not yet a universal cure. AL treatment rapidly suppresses the plasma-cell clone—most commonly daratumumab plus bortezomib, cyclophosphamide, and dexamethasone (Dara-VCd)—alongside organ support and, for selected patients, autologous stem-cell transplantation. ATTR treatment uses transthyretin stabilizers or liver-directed RNA-silencing drugs to slow further protein production and deposition; in the United States, vutrisiran is approved for ATTR cardiomyopathy to reduce cardiovascular mortality and heart-failure events. FDA approval of daratumumab combination FDA approval information for vutrisiran

Scope of Recent Research (2020–present)

Research activity has expanded quickly since 2020, especially in ATTR, where the central questions are whether a one-time gene edit can permanently stop transthyretin production and whether antibodies can physically clear existing deposits, and in AL, where the priorities are eliminating the plasma-cell clone more deeply and removing persistent light-chain fibrils from organs. These are credible routes toward functional cure—durable elimination of the protein source plus recovery from deposits—but no therapy has yet been shown to reliably reverse all established organ damage or cure systemic amyloidosis across patients. Current landscape of ATTR therapies Systemic light-chain and transthyretin amyloidosis: treatment advancements

Major Breakthroughs and Emerging Therapies

For ATTR, RNA interference has provided the strongest recent evidence that deeply lowering the disease-causing protein can change clinical outcomes. In the phase 3 HELIOS-B trial, the subcutaneous small-interfering RNA drug vutrisiran lowered the combined risk of death or recurrent cardiovascular events versus placebo in ATTR cardiomyopathy, while also preserving walking capacity and quality of life. It is a disease-modifying treatment rather than a cure because dosing is continued and pre-existing fibrils can remain in tissue. HELIOS-B vutrisiran trial

Gene editing is a more explicitly curative strategy for ATTR. NTLA-2001, now also known as nexiguran ziclumeran, packages messenger RNA for the CRISPR-Cas9 enzyme and a guide RNA in a liver-targeted lipid nanoparticle; after one intravenous infusion, the system disables the liver’s TTR gene. In the initial phase 1 report involving six people with hereditary ATTR polyneuropathy, the higher dose reduced circulating transthyretin by a mean of 87% at day 28, with mainly mild adverse events. This demonstrated that in-body CRISPR editing can durably reduce an amyloid precursor protein, but it did not establish restoration of damaged nerves or hearts, long-term safety, or a cure. In vivo CRISPR editing for ATTR

A complementary strategy is amyloid depletion: antibodies bind misfolded fibrils already deposited in organs and recruit immune cells to remove them. In ATTR cardiomyopathy, NI006—subsequently developed as cliramitug/ALXN2220—was tested in a 40-person randomized phase 1 study specifically designed to assess antibody-mediated removal of cardiac ATTR deposits. In AL amyloidosis, CAEL-101 targets light-chain fibrils; its phase 1a/b study found no dose-limiting toxicity and reported biomarker or imaging-defined organ responses in 15 of 24 evaluable patients. These early studies are important because stopping new protein production alone may leave patients with dangerous residual heart, kidney, or nerve deposits. NI006 phase 1 trial CAEL-101 phase 1a/b trial

For AL amyloidosis, plasma-cell-directed therapy has become substantially more effective. In the phase 3 ANDROMEDA trial, adding anti-CD38 antibody daratumumab to bortezomib, cyclophosphamide, and dexamethasone increased hematologic complete response from 18.1% to 53.3% and improved cardiac and renal response rates at six months. More experimental approaches seek deeper, potentially treatment-free remissions: anti-BCMA CAR-T cells are engineered immune cells that recognize the B-cell maturation antigen on plasma cells. In a phase Ia/Ib cohort of 16 heavily pretreated AL patients, 15 achieved a hematologic response and 12 achieved complete response, though advanced cardiac disease, cytokine-release syndrome, and deaths during follow-up illustrate the considerable risk in this medically fragile population. ANDROMEDA trial BCMA CAR-T trial in relapsed AL

Clinical Trials and Experimental Approaches

Notable recent trials span protein suppression, gene editing, deposit clearance, and cellular therapy. HELIOS-B was a phase 3 Alnylam-sponsored trial of vutrisiran in 655 participants with ATTR cardiomyopathy and reported a hazard ratio of 0.72 for death or recurrent cardiovascular events versus placebo. Intellia Therapeutics and Regeneron sponsored the ongoing clinical development of NTLA-2001/nexiguran ziclumeran, following its initial phase 1 demonstration of large, dose-dependent transthyretin reductions after one infusion. HELIOS-B vutrisiran trial In vivo CRISPR editing for ATTR NTLA-2001 clinical-trial record

Deposit-removal trials are especially relevant to a cure-oriented approach. Alexion’s phase 3 CAEL-101 program combines the anti-fibril antibody with standard plasma-cell therapy in newly diagnosed, high-risk Mayo stage IIIa AL amyloidosis; the study tests whether adding deposit clearance improves survival and organ outcomes beyond source suppression alone. The investigator-led HBI0101 anti-BCMA CAR-T study in relapsed/refractory AL amyloidosis is phase Ia/Ib, and its published results support further testing with careful selection and management of patients with cardiac involvement. CAEL-101 phase 3 protocol BCMA CAR-T trial in relapsed AL HBI0101 clinical-trial record

Methodologies and Scientific Approaches

Researchers first establish the exact amyloid type, because a treatment that suppresses light-chain production will not treat ATTR, and vice versa. For AL, diagnosis and monitoring combine tissue confirmation and protein typing—ideally with laser-capture mass spectrometry—with serum free-light-chain testing, cardiac biomarkers such as NT-proBNP and troponin, kidney protein measurements, and imaging. Deep response is increasingly assessed with highly sensitive next-generation flow cytometry for minimal residual disease, meaning very small numbers of remaining abnormal plasma cells. AL amyloidosis: 2024 update Minimal residual disease and organ response

Cure-oriented platforms then attack two biological targets: the source protein and the deposited fibrils. Lipid nanoparticles deliver CRISPR components selectively to hepatocytes, the liver cells that make transthyretin, while anti-fibril antibodies are designed to mark deposits for phagocytic immune-cell removal. Trials use serial transthyretin or free-light-chain levels as source-suppression biomarkers, together with cardiac MRI, echocardiography, nuclear imaging, NT-proBNP, walking tests, and patient-reported quality-of-life measures to determine whether organs are actually recovering. In vivo CRISPR editing for ATTR CAEL-101 phase 1a/b trial NI006 phase 1 trial

Leading Institutions and Funding

Major academic centers include the National Amyloidosis Centre at University College London and Royal Free Hospital, Mayo Clinic, Columbia University, the Amyloidosis Research and Treatment Center at IRCCS Policlinico San Matteo and the University of Pavia, and Hadassah Medical Center/Hebrew University of Jerusalem. These centers contribute specialized diagnosis, cardiac and neurologic assessment, transplant expertise, laboratory amyloid typing, and early-phase trials. HELIOS-B vutrisiran trial AL amyloidosis: 2024 update BCMA CAR-T trial in relapsed AL

Industry funding has been central to recent clinical progress: Alnylam funded HELIOS-B; Intellia Therapeutics and Regeneron funded the initial CRISPR ATTR study; Janssen funded ANDROMEDA; and Alexion sponsors the current phase 3 CAEL-101 protocol. This mix of industry-led development and specialized academic trial networks has enabled studies that would be difficult in a rare, clinically diverse disease. HELIOS-B vutrisiran trial In vivo CRISPR editing for ATTR ANDROMEDA trial CAEL-101 phase 3 protocol

Strengths, Limitations, and Challenges

The field’s major strength is that it now has plausible interventions for each step of disease biology: suppressing production of the harmful protein, eliminating the AL plasma-cell clone, and potentially clearing tissue deposits. Vutrisiran’s phase 3 outcome benefit and the early CRISPR and anti-fibril-antibody results show that amyloidosis is becoming biologically tractable rather than merely manageable. HELIOS-B vutrisiran trial In vivo CRISPR editing for ATTR CAEL-101 phase 1a/b trial

Important limitations remain. Permanent gene editing requires long-term surveillance for unintended edits and liver-related safety issues; fibril-clearing antibodies must prove that reducing deposits produces durable clinical benefit; and CAR-T therapy can trigger cytokine-release syndrome or destabilize patients whose hearts, kidneys, or autonomic nerves are already severely impaired. Delayed diagnosis, imperfect access to expert centers, high treatment costs, and irreversible late-stage organ injury can also prevent an otherwise effective source-targeted treatment from becoming a true cure for an individual patient. In vivo CRISPR editing for ATTR BCMA CAR-T trial in relapsed AL ASH guidelines on AL diagnosis

Outlook and Future Directions

As of October 9, 2026, amyloidosis research is closest to a functional cure when therapies can be combined: deeply and durably eliminate the precursor protein or plasma-cell clone, then safely remove existing fibrils before organ injury becomes permanent. The milestones to watch are long-term clinical and safety results from one-time ATTR gene editing, randomized evidence that anti-fibril antibodies restore heart and kidney function and extend survival, and confirmation that BCMA-directed cellular therapies can produce durable, low-toxicity AL remissions in patients with substantial cardiac disease. Until those outcomes are demonstrated, the most accurate conclusion is that treatment is improving rapidly, but a broadly reliable cure remains investigational. Current landscape of ATTR therapies Systemic light-chain and transthyretin amyloidosis: treatment advancements

References

Don't see your disease? Request a report